Clinical Trial Update: Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD). [Phase 4]

View source ↗

Summary

Phase 4 trial comparing fluticasone furoate/vilanterol inhalation powder to vilanterol alone in COPD, focusing on bone mineral density outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Fluticasone Furoate/Vilanterol (fluticasone furoate/vilanterol)
• Vilanterol (vilanterol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: COMPLETED | Results posted: 2019-04-10